UCB SA (OTCMKTS:UCBJY – Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $101.51 and last traded at $101.16, with a volume of 432584 shares changing hands. The stock had previously closed at $95.06.
UCB Price Performance
The firm has a fifty day moving average of $97.37 and a 200-day moving average of $94.68. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- What Are Dividend Contenders? Investing in Dividend Contenders
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- What is Short Interest? How to Use It
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Why is the Ex-Dividend Date Significant to Investors?
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.